Key Highlights
- SELLAS (SLS) has 29.2% of its float sold short with 8.6 days to cover.
- The Phase 3 REGAL trial of galinpepimut-S in AML has been described as nearing its readout; SLS009 is also in an AML trial.
- SLS rose to $12.00 pre-market; the market Capitalization is about $2.4 billion.
SELLAS Life Sciences (NASDAQ:SLS) rose to $12.00 in pre-market trading, outpacing biotech peers, as investors await the "imminent" Phase 3 REGAL readout for its galinpepimut-S cancer Vaccine in acute myeloid leukemia. The stock has soared about 600% in a year, 29.2% of its float is sold short, and a law-firm investigation adds another layer of drama to one of 2026's most binary biotech bets.
SELLAS Life Sciences' short interest stands at 29.2 percent of the float, with 8.6 days needed to cover. Short sellers borrow and sell shares expecting a decline, and with 8.6 days to cover, a positive trial result could force them to buy back quickly, the setup for a squeeze.
This is a binary situation. After a roughly 600% run over 52 weeks, many shorts appear to be betting the REGAL data disappoints, while longs expect a win. SELLAS also presented preclinical data for SLS009 in pancreatic cancer at AACR on Sept. 2, and a law firm has opened an investigation on behalf of investors. Alliance Global raised its target to $35.
SELLAS (SLS) Outpaces Biotech Peers
Vera Therapeutics rose 0.3% and Mineralys fell 4.5%, while SLS moved higher. Participation was subdued. The 52-week range is $1.39 to $15.88.
SLS Technical Levels
First support is $10.20, followed by $7.07. First resistance is $16.07, above the 52-week high, and the next is $18.81. A move through $16.07 would put the stock in record territory and could pressure short sellers sharply.
A Tiny Company With a Big Valuation
SELLAS has no revenue, 13 employees and $138.34 million of cash and equivalents. It trades at 17.6 times book value. Analysts rate the stock a Buy with an average target of about $32.50, though only two analysts cover it.
Peers Moving on This News
- Vera Therapeutics (NASDAQ:VERA) up 0.3%
- Mineralys Therapeutics (NASDAQ:MLYS) down 4.5%






Please wait processing your request...